Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples